BACKGROUND AND OBJECTIVES: IGF-1 deficiency links to malnutrition in CKD patients; however, it is not clear to what extent it associates with survival among these patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serum IGF-1 and other biochemical, clinical (subjective global assessment), and densitometric (dual energy x-ray absorptiometry) markers of nutritional status and mineral and bone metabolism were measured in a cohort of 365 Swedish clinically stable CKD stage 5 patients (median age of 53 years) initiating dialysis between 1994 and 2009; in 207 patients, measurements were also taken after 1 year of dialysis. Deaths were registered during a median follow-up of 5 years. Associations of mortality with baseline IGF-1 and changes of IGF-1 after 1 year of dialysis were evaluated by Cox models. RESULTS: At baseline, IGF-1 concentrations associated negatively with age, diabetes mellitus, cardiovascular disease, poor nutritional status, IL-6, and osteoprotegerin and positively with body fat mass, bone mineral density, serum phosphate, calcium, and fibroblast growth factor-23. At 1 year, IGF-1 had increased by 33%. In multivariate regression, low age, diabetes mellitus, and high serum phosphate and calcium associated with IGF-1 at baseline, and in a mixed model, these factors, together with high fat body mass, associated with changes of IGF-1 during the first 1 year of dialysis. Adjusting for calendar year of inclusion, age, sex, diabetes mellitus, cardiovascular disease, IL-6, and poor nutritional status, a 1 SD higher level of IGF-1 at baseline associated with lower mortality risk (hazard ratio, 0.57; 95% confidence interval, 0.32 to 0.98). Persistently low or decreasing IGF-1 levels during the first 1 year on dialysis predicted worse survival (adjusted hazard ratio, 2.19; 95% confidence interval, 1.06 to 4.50). CONCLUSION: In incident dialysis patients, low serum IGF-1 associates with body composition and markers of mineral and bone metabolism, and it predicts increased mortality risk.
BACKGROUND AND OBJECTIVES:IGF-1deficiency links to malnutrition in CKDpatients; however, it is not clear to what extent it associates with survival among these patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serum IGF-1 and other biochemical, clinical (subjective global assessment), and densitometric (dual energy x-ray absorptiometry) markers of nutritional status and mineral and bone metabolism were measured in a cohort of 365 Swedish clinically stable CKD stage 5 patients (median age of 53 years) initiating dialysis between 1994 and 2009; in 207 patients, measurements were also taken after 1 year of dialysis. Deaths were registered during a median follow-up of 5 years. Associations of mortality with baseline IGF-1 and changes of IGF-1 after 1 year of dialysis were evaluated by Cox models. RESULTS: At baseline, IGF-1 concentrations associated negatively with age, diabetes mellitus, cardiovascular disease, poor nutritional status, IL-6, and osteoprotegerin and positively with body fat mass, bone mineral density, serum phosphate, calcium, and fibroblast growth factor-23. At 1 year, IGF-1 had increased by 33%. In multivariate regression, low age, diabetes mellitus, and high serum phosphate and calcium associated with IGF-1 at baseline, and in a mixed model, these factors, together with high fat body mass, associated with changes of IGF-1 during the first 1 year of dialysis. Adjusting for calendar year of inclusion, age, sex, diabetes mellitus, cardiovascular disease, IL-6, and poor nutritional status, a 1 SD higher level of IGF-1 at baseline associated with lower mortality risk (hazard ratio, 0.57; 95% confidence interval, 0.32 to 0.98). Persistently low or decreasing IGF-1 levels during the first 1 year on dialysis predicted worse survival (adjusted hazard ratio, 2.19; 95% confidence interval, 1.06 to 4.50). CONCLUSION: In incident dialysis patients, low serum IGF-1 associates with body composition and markers of mineral and bone metabolism, and it predicts increased mortality risk.
Authors: C J Rosen; H P Dimai; D Vereault; L R Donahue; W G Beamer; J Farley; S Linkhart; T Linkhart; S Mohan; D J Baylink Journal: Bone Date: 1997-09 Impact factor: 4.398
Authors: G Sun; J Gagnon; Y C Chagnon; L Pérusse; J P Després; A S Leon; J H Wilmore; J S Skinner; I Borecki; D C Rao; C Bouchard Journal: Int J Obes Relat Metab Disord Date: 1999-09
Authors: A R Qureshi; A Alvestrand; A Danielsson; J C Divino-Filho; A Gutierrez; B Lindholm; J Bergström Journal: Kidney Int Date: 1998-03 Impact factor: 10.612
Authors: Elżbieta Cecerska-Heryć; Rafał Heryć; Magda Wiśniewska; Anna Michalczyk; Barbara Dołęgowska Journal: Int Urol Nephrol Date: 2019-06-13 Impact factor: 2.370
Authors: Jia Sun; Jonas Axelsson; Anna Machowska; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Karin Lindström; Peter Stenvinkel; Abdul Rashid Qureshi Journal: Clin J Am Soc Nephrol Date: 2016-06-08 Impact factor: 8.237
Authors: Stefanie de Groot; Hans Gelderblom; Marta Fiocco; Judith Vmg Bovée; Jacobus Jm van der Hoeven; Hanno Pijl; Judith R Kroep Journal: Onco Targets Ther Date: 2017-06-13 Impact factor: 4.147
Authors: Jamal Rahmani; Alberto Montesanto; Edward Giovannucci; Hamid Zand; Meisam Barati; John J Kopchick; Mario G Mirisola; Vincenzo Lagani; Hiba Bawadi; Raffaele Vardavas; Alessandro Laviano; Kaare Christensen; Giuseppe Passarino; Valter D Longo Journal: Aging Cell Date: 2022-01-20 Impact factor: 9.304